Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction in Young Leukemia Patients Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction in Young Leukemia Patients

Arsenic trioxide consolidation allows for use of lower anthracycline doses while preserving excellent survival outcomes in young patients with acute promyelocytic leukemia (APL), according to results from the Children ' s Oncology Group AAML0631 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news